Aberdeen Group plc Boosts Stake in Oculis Holding AG

Investment firm increases ownership in biotech company developing novel ophthalmic therapies

Apr. 5, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, a prominent investment management firm, has increased its stake in Oculis Holding AG, a clinical-stage biopharmaceutical company focused on developing innovative eye care treatments. According to a recent SEC filing, Aberdeen Group boosted its position in Oculis by 39.4% during the fourth quarter, now owning approximately 3.34% of the company's outstanding shares.

Why it matters

This investment signals Aberdeen Group's confidence in Oculis' pipeline of novel ophthalmic therapies, which include a topical dexamethasone formulation for diabetic macular edema and a nasal spray for dry eye disease. As Oculis continues to advance its clinical programs, this increased institutional backing could provide valuable support and validation.

The details

In its latest 13F filing with the SEC, Aberdeen Group reported owning 1,746,946 shares of Oculis, up from 1,253,119 shares held in the previous quarter. This additional investment of nearly 500,000 shares represents a 39.4% increase in the firm's position. Oculis, which is headquartered in Basel, Switzerland and has a presence in Cambridge, Massachusetts, is developing a portfolio of topical and nasal spray formulations aimed at addressing various retinal, neuro-ophthalmic, and ocular surface diseases.

  • Aberdeen Group plc increased its stake in Oculis Holding AG during the fourth quarter of 2025.
  • Oculis Holding AG is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Basel, Switzerland.

The players

Aberdeen Group plc

A prominent global investment management firm that has increased its ownership stake in Oculis Holding AG, a biotech company developing novel ophthalmic therapies.

Oculis Holding AG

A clinical-stage biopharmaceutical company focused on developing innovative eye care treatments, including a topical dexamethasone formulation for diabetic macular edema and a nasal spray for dry eye disease.

Got photos? Submit your photos here. ›

The takeaway

Aberdeen Group's increased investment in Oculis Holding AG reflects growing institutional confidence in the biotech company's pipeline of novel ophthalmic therapies. As Oculis continues to advance its clinical programs, this backing from a prominent investment firm could provide valuable support and validation for the company's efforts to address unmet needs in eye care.